loading page

Development of Bing-Neel syndrome Despite Ibrutinib Therapy for Waldenstrom Macroglobulinemia: Next Steps in Management and Review of Future Directions
  • +2
  • Lukas Delasos,
  • Deep Phachu,
  • Nishka Shetty,
  • Melissa Sepulveda-Ramos,
  • James Vredenburgh
Lukas Delasos
University of Connecticut Health Center
Author Profile
Deep Phachu
University of Connecticut Health Center
Author Profile
Nishka Shetty
University of Connecticut Health Center
Author Profile
Melissa Sepulveda-Ramos
Hartford Hospital Department of Pathology and Laboratory Medicine
Author Profile
James Vredenburgh
Smilow Cancer Hospital at St. Francis
Author Profile

Peer review status:UNDER REVIEW

12 May 2020Submitted to Clinical Case Reports
13 May 2020Assigned to Editor
13 May 2020Submission Checks Completed
15 May 2020Reviewer(s) Assigned
08 Jun 2020Review(s) Completed, Editorial Evaluation Pending

Abstract

Bing-Neel syndrome (BNS) remains a rare complication of Waldenstrom Macroglobulinemia. Given the paucity of this disease, treatment guidelines are based on small clinical trials with limited participants. Here we present a case of BNS that developed while on ibrutinib therapy, followed by a review of the next steps in management.